Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

被引：0
|
作者：
Tiacci, Enrico [1 ,2 ]
De Carolis, Luca [1 ,2 ]
Capponi, Monia [1 ,2 ]
Falcinelli, Flavio [1 ,2 ]
Zaja, Francesco [3 ,4 ]
Pulsoni, Alessandro [5 ]
Simonetti, Edoardo [1 ,2 ]
Montechiarello, Elisa [6 ]
Romano, Alessandra [7 ]
Olivieri, Jacopo [8 ]
Mancini, Alessandro [1 ,2 ]
D'Elia, Gianna Maria [9 ,10 ]
Foa, Robin [9 ,10 ]
Frezzato, Maurizio [11 ]
Falini, Brunangelo [2 ]
机构：
[1] Univ & Hosp Perugia, Inst Hematol, Perugia, Italy
[2] Univ & Hosp Perugia, Ctr Hematooncol Res, Perugia, Italy
[3] Univ Trieste, DSM, Trieste, Italy
[4] Azienda Sanit Univ Giuliano Isontina, UCO Ematologia, Trieste, Italy
[5] Univ Sapienza, SM Goretti Hosp, Hematol, Latina, Italy
[6] Hosp Reggio Calabria, Hematol, Reggio Di Calabria, Italy
[7] Univ & Hosp Catania, Hematol, Catania, Italy
[8] Azienda Sanit Univ Integrata Udine, Ctr Trapianti & Terapie Cellulari Carlo Melzi, Clin Ematol, Udine, Italy
[9] Univ Sapienza, Hematol, Rome, Italy
[10] Hosp Umberto I, Rome, Italy
[11] Hosp Vicenza, Hematol, Vicenza, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Inotuzumab ozogamicin (InO) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) in the global phase 3 randomized controlled ino-vate trial: efficacy and safety by age and prior therapy
    Stelljes, M.
    Kreuzer, K. -A
    Deangelo, D. J.
    Advani, A. S.
    Goekbuget, N.
    Liedtke, M.
    Stock, W.
    Martinelli, G.
    O'Brien, S.
    Wang, K.
    Wang, T.
    Paccagnella, M. L.
    Sleight, B.
    Vandendries, E.
    Jabbour, E. J.
    Kantarjian, H. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 201 - 202
  • [32] Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
    Schuster, Stephen J.
    Dickinson, Michael J.
    Dreyling, Martin H.
    Martinez, Joaquin
    Kolstad, Arne
    Butler, Jason Paul
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Abdelhady, Ahmed M.
    Zia, Aiesha
    Morisse, Mony Chenda
    Fowler, Nathan Hale
    Thieblemont, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status
    Advani, Anjali S.
    Jabbour, Elias J.
    Stelljes, Matthias
    Stock, Wendy
    Liedtke, Michaela
    Goekbuget, Nicola
    O'Brien, Susan M.
    White, Jane Liang
    Wang, Tao
    Laird, A. Douglas
    Vandendries, Erik
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [34] Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
    Abramson, Jeremy S.
    Palomba, Maria Lia
    Gordon, Leo I.
    Lunning, Matthew A.
    Wang, Michael L.
    Arnason, Jon E.
    Mehta, Amitkumar
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison R.
    Solomon, Scott R.
    Ghosh, Nilanjan
    Albertson, Tina
    Garcia, Jacob
    Kostic, Ana
    Li, Daniel
    Kim, Yeonhee
    Siddiqi, Tanya
    BLOOD, 2019, 134
  • [35] Polatuzumab vedotin plus obinutuzumab plus venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.
    Bannerji, Rajat
    Yuen, Sam
    Phillips, Tycel Jovelle
    Arthur, Christopher
    Isufi, Iris
    Marlton, Paula
    Seymour, John Francis
    Corradini, Paolo
    Molinari, Annalia
    Gritti, Giuseppe
    Emmons, Robert
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Zarnestra™ (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML):: Results of a multicenter phase 2 study.
    Harousseau, JL
    Reiffers, J
    Lowenberg, B
    Thomas, X
    Huguet, F
    Fenaux, P
    Stone, RM
    Lancet, J
    Arani, R
    Rackoff, W
    Thibault, A
    BLOOD, 2003, 102 (11) : 176A - 176A
  • [37] Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) In Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Abramson, Jeremy
    Palomba, M. Lia
    Gordon, Leo
    Lunning, Matthew
    Wang, Michael
    Arnason, Jon
    Mehta, Amitkumar
    Purev, Enkhtsetseg
    Maloney, David
    Andreadis, Charalambos
    Sehgal, Alison
    Solomon, Scott
    Ghosh, Nilanjan
    Albertson, Tina
    Garcia, Jacob
    Kostic, Aria
    Li, Daniel
    Kim, Yeonhee
    Siddiqi, Tanya
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 215 - 215
  • [38] Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis
    Buechner, Jochen
    Grupp, Stephan A.
    Maude, Shannon L.
    Boyer, Michael
    Bittencourt, Henrique
    Laetsch, Theodore W.
    Bader, Peter
    Verneris, Michael R.
    Stefanski, Heather
    Myers, Gary Douglas
    Qayed, Muna
    Pulsipher, Michael A.
    De Moerloose, Barbara
    Hiramatsu, Hidefumi
    Schlis, Krysta
    Davis, Kara
    Martin, Paul L.
    Nemecek, Eneida
    Peters, Christina
    Wood, Patricia
    Taran, Tetiana
    Mueller, Karen Thudium
    Zhang, Yiyun
    Rives, Susana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S263 - S264
  • [39] GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS
    Buechner, J.
    Grupp, S. A.
    Maude, S. L.
    Boyer, M.
    Bittencourt, H.
    Laetsch, T. W.
    Bader, P.
    Verneris, M. R.
    Stefanski, H.
    Myers, G. D.
    Qayed, M.
    Pulsipher, M. A.
    De Moerloose, B.
    Hiramatsu, H.
    Schlis, K.
    Davis, K.
    Martin, P. L.
    Nemecek, E.
    Peters, C.
    Wood, P.
    Taran, T.
    Mueller, K. Thudium
    Zhang, Y.
    Rives, S.
    HAEMATOLOGICA, 2017, 102 : 178 - 178
  • [40] Atezolizumab plus obinutuzumab plus venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
    Herbaux, Charles
    Casasnovas, Olivier
    Feugier, Pierre
    Damaj, Gandhi
    Bouabdallah, Reda
    Guidez, Stephanie
    Ysebaert, Loic
    Tilly, Herve
    Le Gouill, Steven
    Fornecker, Luc
    Daguindau, Nicolas
    Morineau, Nadine
    Haioun, Corinne
    Gyan, Emmanuel
    Sibon, David
    Gressin, Remy
    Houot, Roch
    Salles, Gilles A.
    Morschhauser, Franck
    Cartron, Guillaume
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345